[go: up one dir, main page]

FR3124509B1 - Nouveaux inhibiteurs de phosphorylation de Elk-1 par ERK1/2 - Google Patents

Nouveaux inhibiteurs de phosphorylation de Elk-1 par ERK1/2 Download PDF

Info

Publication number
FR3124509B1
FR3124509B1 FR2106874A FR2106874A FR3124509B1 FR 3124509 B1 FR3124509 B1 FR 3124509B1 FR 2106874 A FR2106874 A FR 2106874A FR 2106874 A FR2106874 A FR 2106874A FR 3124509 B1 FR3124509 B1 FR 3124509B1
Authority
FR
France
Prior art keywords
elk
erk1
phosphorylation
novel inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2106874A
Other languages
English (en)
Other versions
FR3124509A1 (fr
Inventor
Jocelyne Caboche
Peter Vanhoutte
Nicolas Pietrancosta
Fabrice Trovero
Mathieu Barrier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melkin Pharmaceuticals
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Ecole Normale Superieure de Paris
Original Assignee
Melkin Pharmaceuticals
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Ecole Normale Superieure de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melkin Pharmaceuticals, Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite, Ecole Normale Superieure de Paris filed Critical Melkin Pharmaceuticals
Priority to FR2106874A priority Critical patent/FR3124509B1/fr
Priority to EP22738610.9A priority patent/EP4359434A1/fr
Priority to PCT/EP2022/067462 priority patent/WO2022269093A1/fr
Publication of FR3124509A1 publication Critical patent/FR3124509A1/fr
Application granted granted Critical
Publication of FR3124509B1 publication Critical patent/FR3124509B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11024—Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Theoretical Computer Science (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention décrit de nouveaux peptides synthétiques qui sont des inhibiteurs de phosphorylation de Elk-1 par les kinases ERK1/2. Une composition pharmaceutique contenant lesdits peptides ainsi que leur utilisation en tant que médicaments sont également décrites. Une méthode d’identification et d’optimisation de nouveaux inhibiteurs de phosphorylation de Elk-1 par ERK1/2 est également décrite.
FR2106874A 2021-06-25 2021-06-25 Nouveaux inhibiteurs de phosphorylation de Elk-1 par ERK1/2 Active FR3124509B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR2106874A FR3124509B1 (fr) 2021-06-25 2021-06-25 Nouveaux inhibiteurs de phosphorylation de Elk-1 par ERK1/2
EP22738610.9A EP4359434A1 (fr) 2021-06-25 2022-06-25 Nouveaux inhibiteurs de phosphorylation de elk-1 par erk1/2
PCT/EP2022/067462 WO2022269093A1 (fr) 2021-06-25 2022-06-25 Nouveaux inhibiteurs de phosphorylation de elk-1 par erk1/2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2106874 2021-06-25
FR2106874A FR3124509B1 (fr) 2021-06-25 2021-06-25 Nouveaux inhibiteurs de phosphorylation de Elk-1 par ERK1/2

Publications (2)

Publication Number Publication Date
FR3124509A1 FR3124509A1 (fr) 2022-12-30
FR3124509B1 true FR3124509B1 (fr) 2025-06-27

Family

ID=77021594

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2106874A Active FR3124509B1 (fr) 2021-06-25 2021-06-25 Nouveaux inhibiteurs de phosphorylation de Elk-1 par ERK1/2

Country Status (3)

Country Link
EP (1) EP4359434A1 (fr)
FR (1) FR3124509B1 (fr)
WO (1) WO2022269093A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1988167T3 (da) * 2005-02-17 2020-07-13 Univ Sorbonne Intracellulære inhiberende peptider
LV13634B (en) 2007-05-02 2007-12-20 Jp Biotechnology Sia Production of ethanol and feedstuffs
EP2172209A1 (fr) * 2008-10-03 2010-04-07 Universite Pierre Et Marie Curie Traitement des troubles de l'humeur et de l'angoisse

Also Published As

Publication number Publication date
EP4359434A1 (fr) 2024-05-01
WO2022269093A1 (fr) 2022-12-29
FR3124509A1 (fr) 2022-12-30

Similar Documents

Publication Publication Date Title
Amobi-McCloud et al. IDO1 expression in ovarian cancer induces PD-1 in T cells via aryl hydrocarbon receptor activation
Silverman et al. Serine 68 phosphorylation of phospholemman: acute isoform-specific activation of cardiac Na/K ATPase
Bunney et al. Fusicoccin signaling reveals 14-3-3 protein function as a novel step in left-right patterning during amphibian embryogenesis
Lang et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs
Aslan et al. The PAK system links Rho GTPase signaling to thrombin-mediated platelet activation
Wang et al. Biochemical tools for tracking proteolysis
Walker et al. Giant fish-killing water bug reveals ancient and dynamic venom evolution in Heteroptera
Eckhard et al. The human dental pulp proteome and N-terminome: levering the unexplored potential of semitryptic peptides enriched by TAILS to identify missing proteins in the human proteome project in underexplored tissues
Pham et al. Transcriptional analysis of lung fibroblasts identifies PIM1 signaling as a driver of aging-associated persistent fibrosis
Selimi et al. Proteomic studies of a single CNS synapse type: the parallel fiber/purkinje cell synapse
Liu et al. Oxidative stress in human gingival fibroblasts from periodontitis versus healthy counterparts
Shevchuk et al. Proteomics: a tool to study platelet function
FR3124509B1 (fr) Nouveaux inhibiteurs de phosphorylation de Elk-1 par ERK1/2
Bulitta et al. Proteomic definition of human mucosal‐associated invariant T cells determines their unique molecular effector phenotype
Van Vaerenbergh et al. Unraveling the venom proteome of the bumblebee (Bombus terrestris) by integrating a combinatorial peptide ligand library approach with FT-ICR MS
Wang et al. Priming integrin α5 promotes human dental pulp stem cells odontogenic differentiation due to extracellular matrix deposition and amplified extracellular matrix‐receptor activity
Mehl et al. Blockage of lamin-A/C loss diminishes the pro-inflammatory macrophage response
FR3124510B1 (fr) Nouveaux inhibiteurs de phosphorylation de Fos par ERK1/2
Asaba et al. Bronchoalveolar lavage single-cell transcriptomics reveals immune dysregulations driving COVID-19 severity
Rahman et al. Restoration of the type I IFN–IL-1 balance through targeted blockade of PTGER4 inhibits autoimmunity in NOD mice
Blundon et al. Proteomic analysis reveals APC-dependent post-translational modifications and identifies a novel regulator of β-catenin
Corgiat et al. The Nab2 RNA-binding protein patterns dendritic and axonal projections through a planar cell polarity-sensitive mechanism
Cho et al. Caspase-mediated nuclear pore complex trimming in cell differentiation and endoplasmic reticulum stress
Krishnan et al. OFFgel‐based multidimensional LC‐MS/MS approach to the cataloguing of the human platelet proteome for an interactomic profile
Kant et al. Human epididymis protein 4 quantification and interaction network analysis in seminal plasma

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20221230

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5